Evidence map›Paper›PMID 33374375›Full record

ReviewPharmaceutics2020

Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations-A Particle Technology Perspective.

Jens Uhlemann, Holger Diedam, Werner Hoheisel, Tobias Schikarski, Wolfgang Peukert

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Jens UhlemannBayer SAS, Environmental Science, 16, Rue Jean-Marie Leclair, 69266 Lyon CEDEX 09, France.ORCID 0000-0002-4969-3659
Holger DiedamBayer AG, Engineering & Technology, Applied Mathematics, Building B106, 102, 51368 Leverkusen, Germany.
Werner HoheiselInvite GmbH, Formulation Technology, Building W 32, 51368 Leverkusen, Germany.
Tobias SchikarskiDepartment Chemical and Biochemical Engineering (CBI), Institute of Particle Technology (LFG) and Center for Functional Particle Systems, Cauerstraße 4, 91058 Erlangen, Germany.ORCID 0000-0002-6657-845X
Wolfgang PeukertDepartment Chemical and Biochemical Engineering (CBI), Institute of Particle Technology (LFG) and Center for Functional Particle Systems, Cauerstraße 4, 91058 Erlangen, Germany.
Bayer (France) · FRBayer (Germany) · DE

Funding

Bayer Technology Services GmbH -Deutsche Forschungsgemeinschaft -
6 · The paper itself

Abstract

Crystalline organic nanoparticles and their amorphous equivalents (ONP) have the potential to become a next-generation formulation technology for dissolution-rate limited biopharmaceutical classification system (BCS) class IIa molecules if the following requisites are met: (i) a quantitative understanding of the bioavailability enhancement benefit versus established formulation technologies and a reliable track record of successful case studies are available; (ii) efficient experimentation workflows with a minimum amount of active ingredient and a high degree of digitalization via, e.g., automation and computer-based experimentation planning are implemented; (iii) the scalability of the nanoparticle-based oral delivery formulation technology from the lab to manufacturing is ensured. Modeling and simulation approaches informed by the pharmaceutical material science paradigm can help to meet these requisites, especially if the entire value chain from formulation to oral delivery is covered. Any comprehensive digitalization of drug formulation requires combining pharmaceutical materials science with the adequate formulation and process technologies on the one hand and quantitative pharmacokinetics and drug administration dynamics in the human body on the other hand. Models for the technical realization of the drug production and the distribution of the pharmaceutical compound in the human body are coupled via the central objective, namely bioavailability. The underlying challenges can only be addressed by hierarchical approaches for property and process design. The tools for multiscale modeling of the here-considered particle processes (e.g., by coupled computational fluid dynamics, population balance models, Noyes-Whitney dissolution kinetics) and physiologically based absorption modeling are available. Significant advances are being made in enhancing the bioavailability of hydrophobic compounds by applying innovative solutions. As examples, the predictive modeling of anti-solvent precipitation is presented, and options for the model development of comminution processes are discussed.

Indexed as

comminutionmodeling and simulationnanocrystaloral bioavailabilitypharmaceutical material sciencepoorly soluble drugprecipitationproduct design

Identifiers

PMID33374375
PMCPMC7823784
OpenAlexW3116263133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.